Sugi Predict

Sugi Predict / Compounds / SCHEMBL688353

SCHEMBL688353

SCHEMBL688353

CCOC(=O)c1c(-c2ccco2)csc1N

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 1.00
▸ MEN1 O00255 5/20 1.00
▸ KMT2A Q03164 5/20 1.00
▸ HSD17B10 Q99714 4/20 1.00
▸ ALOX15 P16050 3/20 1.00
▸ TDP1 Q9NUW8 3/20 1.00
▸ MAPT P10636 5/20 0.67
▸ MAPK1 P28482 2/20 0.67
▸ CASP1 P29466 1/20 0.67
▸ CASP7 P55210 1/20 0.67
▸ GAA P10253 1/20 0.62
▸ KEAP1 Q14145 1/20 0.62
▸ PRKCZ Q05513 8/20 0.61
▸ HPGD P15428 1/20 0.60
▸ MPI P34949 1/20 0.58
▸ USP2 O75604 1/20 0.58
▸ PRKCI P41743 2/20 0.56
▸ PKM P14618 2/20 0.56
▸ POLB P06746 1/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2183272 0.85 ALDH1A1 (0.74) ALDH1A1MEN1KMT2AHSD17B10ALOX15
SCHEMBL690278 0.79 PRKCZ (0.84) ALDH1A1MEN1KMT2AHSD17B10ALOX15
SCHEMBL1190649 0.79 PRKCZ (0.80) ALDH1A1MEN1KMT2AHSD17B10ALOX15
SCHEMBL2988135 0.78 ALDH1A1 (0.64) ALDH1A1MEN1KMT2AHSD17B10ALOX15
SCHEMBL1554267 0.77 PRKCZ (0.69) ALDH1A1MEN1KMT2AHSD17B10ALOX15
SCHEMBL689612 0.77 HSD17B10 (0.77) ALDH1A1MEN1KMT2AHSD17B10ALOX15
SCHEMBL689452 0.76 PRKCZ (0.80) ALDH1A1MEN1KMT2AHSD17B10ALOX15
SCHEMBL689546 0.76 ALDH1A1 (1.00) ALDH1A1MEN1KMT2AHSD17B10ALOX15
SCHEMBL17988263 0.76 ALDH1A1 (0.61) ALDH1A1MEN1KMT2AHSD17B10ALOX15
SCHEMBL8289654 0.76 PRKCZ (1.00) ALDH1A1MEN1KMT2AHSD17B10ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118619968-A Dihydrothienopyrimidino pyrido indol-4-one derivative and application thereof 新疆工程学院 2024-09-10 — — CN disclosed
US-8338623-B2 N-{3-[(2,5-dimethylmorpholin-4-yl)carbonyl]-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl}hexahydro-2,5-methanopentalene-3a(1H)-carboxamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants ABBVIE INC. (US) 2012-12-25 — — US disclosed
EP-1953148-B1 HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2012-02-29 — — EP disclosed
US-7915267-B2 Heterocyclic amide compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-03-29 — — US disclosed
US-7713966-B2 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2010-05-11 — — US disclosed
US-7713966-B2 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2010-05-11 — — US disclosed
EP-2176219-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS Abbott Laboratories (US) 2010-04-21 — — EP disclosed
US-20100010017-A1 CERTAIN THIENOPYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-14 — — US disclosed
US-20100010017-A1 CERTAIN THIENOPYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-14 — — US disclosed
US-20100010017-A1 CERTAIN THIENOPYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-14 — — US disclosed
US-20070259896-A1 Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2007-11-08 — — US disclosed
US-20070259896-A1 Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2007-11-08 — — US disclosed
EP-1831229-A1 THIENOPYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS Memory Pharmaceutical Corporation (US) 2007-09-12 — — EP disclosed
WO-2006071988-A1 THIENOPYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS MEMORY PHARMACEUTICALS CORP. (US) 2006-07-06 — — WO disclosed
WO-2006071988-A1 THIENOPYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS MEMORY PHARMACEUTICALS CORP. (US) 2006-07-06 — — WO disclosed
EP-1018514-B1 NF-$g(k)B INHIBITORS CONTAINING INDAN DERIVATIVES AS THE ACTIVE INGREDIENT DAIICHI SUNTORY PHARMA CO LTD (JP) 2004-05-12 — — EP disclosed
US-6734180-B1 NF-κB inhibitor comprising an indan derivative as an active ingredient DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2004-05-11 — — US disclosed
US-6703421-B1 ADMINISTERING NF-KAPPA B INHIBITOR DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2004-03-09 — — US disclosed
EP-1132093-A1 PREVENTIVES OR REMEDIES FOR MYOCARDITIS, DILATED CARDIOMYOPATHY AND CARDIAC INSUFFICIENCY CONTAINING NF-KAPPA B INHIBITORS AS THE ACTIVE INGREDIENT SUNTORY LIMITED (JP) 2001-09-12 — — EP disclosed
EP-1018514-A1 NF-$g(k)B INHIBITORS CONTAINING INDAN DERIVATIVES AS THE ACTIVE INGREDIENT SUNTORY LIMITED (JP) 2000-07-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010017-A1 CERTAIN THIENOPYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS PDE12, PDE4A, PDE7A ALDH1A1 357/4885MEN1 4246/4885KMT2A 1622/4885
US-20070259896-A1 Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors PDE12, PDE7A, PDE7B ALDH1A1 576/4885MEN1 4155/4885KMT2A 1987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.